EPL Q2 FY27 Revenue Surges 30% to ₹15,674 Million on Broad-Based Growth
EPL Limited reported a 30% year-on-year revenue growth to ₹15,674 million in Q2 FY27. Underlying revenue growth was 20.3%, and EBITDA grew 17.6% to ₹2,960 million, with a 20.4% underlying EBITDA margin. The company reaffirmed guidance for high-teens revenue growth and 20% EBITDA margins. The proposed merger with Indovida is advancing.
The announcement details robust financial performance, strategic growth initiatives, and significant progress on a major corporate merger, all of which are material to investors.
The company reported strong financial results with significant revenue and EBITDA growth, exceeding previous performance and reaffirming positive future guidance. The progress on the merger also adds to the positive sentiment.
EPL Limited announced outstanding financial results for the second quarter ended September 30, 2026 (Q2 FY27), with revenue accelerating by 30% year-on-year to ₹15,674 million. This strong performance was driven by broad-based growth across all regions and categories, demonstrating the resilience of its business model.
Growth was particularly robust in the Beauty & Cosmetics segment, which surged by 42.9%. Personal Care & Beyond now constitutes 55% of the total portfolio, marking a significant expansion. Underlying revenue growth, excluding the impact of inflation-led pricing, remained strong at over 20.3%.
EBITDA increased by 17.6% to ₹2,960 million, marking the 16th consecutive quarter of double-digit EBITDA growth. The underlying EBITDA margin was sustained at a healthy 20.4%, with the company successfully passing on cost increases through judicious pricing. Profit After Tax (PAT) for the quarter stood at ₹1,101 million.
Mr. Hemant Bakshi, MD & Global CEO, highlighted the strategic success, noting that the Beauty & Cosmetics category surpassed Oral Care to become the largest category in September. He reaffirmed the company's near-term guidance of high-teens revenue growth and 20% underlying EBITDA margins.
Strategic highlights include strong double-digit revenue growth across all regions, with East Asia Pacific growing 40.2% and Europe by 30.4%. Sustainable tube formats contributed 41% of total sales year-to-date. The proposed merger with Indovida is advancing significantly, with EPL filing its application with the Hon'ble NCLT Mumbai on October 23, 2026, and remains confident of completion within expected timelines.
Looking ahead, EPL retains its guidance of high-teens revenue growth and a 20% underlying EBITDA margin target, focusing on strengthening market leadership, accelerating growth in emerging markets, and expanding its product portfolio beyond tubes.
What to do with a filing like this
EPL Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by EPL Limited. Read the original for the full detail.